Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – What’s Next?

Oculis Holding AG (NASDAQ:OCS) saw unusually-high trading volume on Monday . Approximately 547,574 shares changed hands during trading, an increase of 12% from the previous session’s volume of 488,176 shares.The stock last traded at $10.7160 and had previously closed at $11.21.

Wall Street Analysts Forecast Growth

OCS has been the subject of several research analyst reports. Stifel Nicolaus lowered their price target on Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 1st. HC Wainwright lowered their price target on Oculis from $47.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Guggenheim lowered their price target on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, Needham & Company LLC lowered their price target on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Oculis Stock Down 5.6%

The stock has a market cap of $613.60 million, a PE ratio of -4.97 and a beta of 0.23. The firm has a fifty day moving average of $26.45 and a 200 day moving average of $24.98. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, equities research analysts anticipate that Oculis Holding AG will post -2.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several large investors have recently bought and sold shares of the business. Gildi lifeyrissjodur acquired a new position in Oculis in the fourth quarter valued at $50,250,000. Aberdeen Group plc boosted its stake in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after acquiring an additional 493,827 shares in the last quarter. SR One Capital Management LP boosted its stake in Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after acquiring an additional 318,522 shares in the last quarter. Perceptive Advisors LLC acquired a new position in Oculis in the fourth quarter valued at $9,862,000. Finally, Alyeska Investment Group L.P. boosted its stake in Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after acquiring an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.